Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
---|---|---|---|---|---|
BREAST | S1706 | Breast, Inflammatory, RT +/- Olaparib | 12-SEP-18 | 238 | 101 |
S2007 | Breast, Brain Mets, Sacituzumab Govitecan | 15-DEC-20 | 186 | 67 | |
S2212 | Breast, TNBC, Neoadj Chemo + Pembro | 21-JUL-23 | 109 | 46 | |
A011801 | BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | 06-JAN-21 | 410 | 199 | |
A012103 | Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | 03-MAY-23 | 31 | 16 | |
EA1181 | BRST, HER2-pCR, Preop THP and Postop HP | 11-FEB-20 | 340 | 148 | |
EA1183 | Brst, Met, FDG PET Assess Response, FEATURE | 02-APR-20 | 123 | 58 | |
MA39 | BREAST, Node-Pos, Reg RT vs No Reg RT | 30-MAY-18 | 358 | 138 | |
NRGBR007 | Breast, Stg I, De-Escalation of Breast RT | 07-JUN-21 | 328 | 154 | |
CCD | S1703 | Met Breast, STM-monitoring v Usual Care | 16-JUL-18 | 225 | 87 |
S1912CD | CREDIT, Fin Counseling to reduce Fin Hardship | 26-JUL-21 | 174 | 66 | |
S2108CD | Genomic Tumor Board vs Usual Practice | 22-AUG-22 | 25 | 31 | |
A191901 | Brst, Text/Motivational Intervention ET Adher | 10-DEC-20 | 224 | 97 | |
A231901C | Breast, Shared Decision Engagement System | 15-JAN-21 | 24 | 6 | |
NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 187 | 88 | |
ERLYTX | S2012 | Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | 02-DEC-21 | 189 | 68 |
A071401 | Prog Meningiomas,SMO/AKT/NF2 Inhib | 28-AUG-15 | 239 | 84 | |
AGCT1531 | Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | 08-MAY-17 | 210 | 113 | |
GI | S1922 | Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 16-DEC-19 | 173 | 57 |
S2001 | Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 04-DEC-20 | 203 | 75 | |
S2104 | Panc,Resect High-risk,Postop Adj Chemo vs Obs | 14-OCT-21 | 151 | 56 | |
S2107 | Colorectal, BRAF mut, Enc + CET +/-Nivo | 06-JUN-22 | 170 | 66 | |
A021602 | PANC, Adv PNET Blinded Cabozantinib v Placebo | 18-JUL-18 | 221 | 94 | |
A021806 | Pancreas, Perioperative vs Adjuvant Chemo | 01-JUL-20 | 281 | 124 | |
A022001 | PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM | 16-MAR-22 | 0 | 2 | |
A022102 | Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo | 11-JAN-23 | 29 | 17 | |
A022104 | Rectal, Loc Adv, Triplet vs Doublet Chemo | 09-NOV-22 | 68 | 45 | |
EA2174 | Esoph, Peri-Op Nivolumab +/- Ipilimumab | 17-JAN-19 | 217 | 96 | |
EA2176 | Anal, Met, Immune Check Pt Inhibition + Chemo | 15-OCT-20 | 194 | 86 | |
EA2182 | Anal, Erly, DECREASE | 12-NOV-19 | 270 | 93 | |
EA2186 | PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | 18-JUN-20 | 303 | 115 | |
EA2192 | Panc, APOLLO | 29-APR-21 | 136 | 72 | |
EA2197 | Gal, Rando Perioperative TX | 22-DEC-20 | 114 | 69 | |
NRGGI004 | Colorectal, Stg IV, dMMR Immuno-Therapy | 07-NOV-17 | 326 | 113 | |
NRGGI005 | COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | 16-DEC-19 | 429 | 163 | |
NRGGI008 | Colon, Stg III, Adj Chemo | 10-MAR-22 | 389 | 156 | |
GU | S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 17-SEP-18 | 340 | 140 |
S1806 | Blad, MIBC, ChemoRT +/- Atezolizumab | 19-APR-19 | 335 | 126 | |
S1931 | RENAL, Stg IV, IO + Nephrectomy. vs IO Only | 16-NOV-20 | 181 | 75 | |
S2200 | pRCC, Adv, Cabo +/- Atezo | 19-SEP-22 | 137 | 56 | |
S2210 | Pros, High Risk, BRCA, Neoadj Carbo | 14-AUG-23 | 38 | 10 | |
A031701 | Bladder, ddGC for MIBC with DDR Tumor Alt | 01-AUG-18 | 139 | 51 | |
A031702 | GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | 12-APR-19 | 252 | 95 | |
A031704 | RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | 09-MAY-19 | 273 | 129 | |
A031801 | GU, mRCC, Cabozantinib +/- Radium-223 | 13-DEC-19 | 97 | 37 | |
A031803 | Blad, NMIBC, Gemcitabine + MK-3475 | 06-JAN-20 | 134 | 56 | |
A031902 | Pros, Adv, Enzalutamide + Rucaparib | 19-FEB-21 | 198 | 86 | |
A032001 | Blad, Met, Cabo +/- Avelumab after Chemo | 10-MAR-22 | 75 | 31 | |
A032101 | Pros, MHSPC ADT Interruption | 15-JUL-22 | 7 | 4 | |
EA8134 | Penile, Local Adv, ILND +/- Chemo or ChemoRT | 08-SEP-17 | 29 | 14 | |
EA8171 | PROS, newly diagnosed, mpMRI for pre-op stagi | 09-JUL-18 | 92 | 49 | |
EA8185 | Blad, Stg III, ChemoRT +/- Durv | 25-AUG-20 | 139 | 55 | |
EA8191 | Pros, Local vs Systemic Thrpy | 08-OCT-20 | 181 | 70 | |
EA8192 | Blad, High Grade UTUC, Durv + Chemo | 06-MAY-21 | 147 | 55 | |
EA8212 | Blad, NMIBC, BRIDGE | 01-DEC-22 | 73 | 48 | |
NRGGU008 | Pros,Node+, Abiraterone acetate + Apalutamide | 05-MAR-20 | 213 | 81 | |
NRGGU009 | Pros, PREDICT-RT | 15-DEC-20 | 386 | 144 | |
NRGGU010 | Pros, Parallel De-Intens & Intens Trials | 03-NOV-21 | 368 | 144 | |
NRGGU011 | Pros, Dbl Blinded RT +/- Androgen Dep Tx | 08-DEC-21 | 178 | 63 | |
LEUK | S1905 | T-ALL/T-LBL, Rel/Ref, OBI-3424 | 02-OCT-23 | 53 | 23 |
S1925 | CLL/SLL, Newly Dx HR, Early vs Delayed V+O | 14-DEC-20 | 248 | 97 | |
A041501 | B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | 01-JUN-17 | 222 | 85 | |
A041701 | AML, Age 60+, Conv Chemo +/- Uproleselan | 16-JAN-19 | 170 | 58 | |
A041703 | ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | 16-NOV-18 | 128 | 54 | |
EA9152 | ALL, T/B-Cell, Venetoclax + Vincristine | 26-APR-18 | 53 | 23 | |
EA9171 | CML, Anti-PD-1 Pembrolizumab + TKIs | 03-OCT-18 | 91 | 40 | |
EA9181 | ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | 14-OCT-20 | 162 | 57 | |
EA9213 | T-ALL, dara-hyal for chemo refractory MRD | 16-JUN-22 | 1 | 1 | |
LUNG | S1827 | SCLC, MRI Surveillance +/- PCI | 10-JAN-20 | 331 | 131 |
S1900E | KRAS G12C: Sotorasib (AMG 510) | 02-APR-21 | 315 | 127 | |
S1900G | EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | 03-APR-23 | 250 | 93 | |
S1914 | NSCLC, High Risk Early Stg, SBRT +/- Atezo | 25-MAR-20 | 321 | 127 | |
S1933 | NSCLC, Stg II-III, RT + Atezo | 15-JUN-20 | 144 | 50 | |
S2302 | NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 06-MAR-23 | 376 | 144 | |
A081801 | ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 03-JUN-20 | 415 | 177 | |
A082002 | Lung, Adv, Systemic Tx +/- SBRT | 21-DEC-21 | 174 | 66 | |
A151216 | ALCHEMIST0 - screening | 18-AUG-14 | 506 | 245 | |
E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 471 | 213 | |
EA5163 | NSCLC, Immunotherapy +/- 2nd line therapy | 28-FEB-19 | 379 | 133 | |
EA5181 | NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 | 09-APR-20 | 296 | 113 | |
EA5182 | NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 22-OCT-20 | 187 | 81 | |
EA5191 | NSCLC, Cabozantinib +/- Nivolumab vs Chemo | 22-MAY-20 | 196 | 80 | |
LUNGMAP | NSCLC, Adv, Master | 28-JAN-19 | 423 | 182 | |
NRGLU002 | LUNG, Limited Met NSCLC, MST vs LCT + MST | 07-APR-17 | 250 | 101 | |
NRGLU005 | LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | 28-MAY-19 | 385 | 134 | |
NRGLU006 | Meso, Stg I-IIIA, Pleurectomy +/- Adj RT | 29-JAN-20 | 77 | 24 | |
R1308 | Lung, Stg II/III, Photon vs Proton Chemo RT | 03-FEB-14 | 42 | 30 | |
LYMPH | S1608 | FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 10-AUG-17 | 207 | 76 |
S1918 | DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 19-MAR-21 | 183 | 73 | |
S2114 | NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 23-FEB-23 | 106 | 28 | |
S2207 | LBCL, Transplant Inelig, Targeted Tx + Tafa | 30-JUN-23 | 20 | 8 | |
ANHL1931 | PMBCL, Chemo-Immunotherapy +/- Nivo | 07-JUN-21 | 203 | 106 | |
E4412 | HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 24-JAN-14 | 95 | 60 | |
EA4151 | Lymph, AHCT +/-Ritux, MRD Neg | 29-AUG-17 | 217 | 83 | |
MELAN | S2000 | MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 23-SEP-20 | 123 | 47 |
S2015 | MELAN, Stg I-II, 1cm v 2cm excision margins | 08-APR-22 | 178 | 69 | |
A091903 | Melan, Resected Mucosal, Adj Nivo +/- Cabo | 01-JUN-22 | 96 | 48 | |
EA6141 | Melan, Adv, Nivolumab+Ipi ± Sargmostim | 10-SEP-15 | 240 | 91 | |
EA6174 | Merkel, Adjuvant Pembrolizumab vs Observation | 23-JUL-18 | 302 | 108 | |
EA6192 | Melan, Adv, Erly Discont of Antibdy Thrpy | 27-AUG-20 | 133 | 50 | |
MMYEL | S1803 | MM, Maintenance, Len vs Len/Dara | 27-JUN-19 | 310 | 114 |
S2209 | MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 30-MAY-23 | 111 | 36 | |
EAA173 | MYEL, SMM, Rd +/- Daratumumab | 30-APR-19 | 237 | 98 | |
EAA181 | Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 27-OCT-20 | 173 | 74 | |
MULT | S2101 | Melan or HNSCC, Adv, Cabo + Nivo | 14-OCT-22 | 160 | 63 |
EAY191-S3 | ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | 06-MAR-23 | 108 | 46 | |
OTHER | A071701 | BRAIN, Met, Geno-guided trial | 15-AUG-19 | 231 | 83 |
A071702 | BRAIN, Blockade Tx in Recurrent Glioblastoma | 30-OCT-20 | 127 | 66 | |
A091802 | cSCC, Advanced Avelumab +/- Cetuximab | 17-MAY-19 | 168 | 51 | |
A151804 | irAEs, National Biorepository to Adv Studies | 31-JAN-20 | 151 | 72 | |
EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 235 | 74 | |
EA3161 | HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | 20-JUN-19 | 245 | 90 | |
EA3163 | Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT | 28-MAR-18 | 102 | 34 | |
EA3191 | HN, High Risk HNSCC, Adj +/- Pembro | 08-JAN-21 | 178 | 74 | |
EAF151 | Brain, GBM, Bev, Blood Volume | 14-APR-17 | 86 | 24 | |
EAY191E4 | ComboMATCH | 07-JUN-23 | 7 | 5 | |
N0577 | BRN, Glio,Tem vs Tem+RT vsRT+PVC | 22-SEP-09 | 288 | 95 | |
NRGBN003 | Mening, Grd II, Observation vs Irradiation | 14-JUN-17 | 245 | 87 | |
NRGBN011 | Brain, Lomustine + Temo vs Temo | 29-NOV-21 | 250 | 84 | |
NRGBN012 | Brain, Pre- vs Post-Op Stereotactic Radiosurg | 31-AUG-22 | 155 | 71 | |
NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 143 | 68 | |
NRGHN005 | HN, early stg P16-pos, randomize de-intensifi | 10-JUL-19 | 386 | 130 | |
NRGHN006 | HN, Erly Stg, Biopsy vs Dissection | 08-JUL-20 | 230 | 74 | |
NRGHN009 | HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | 27-OCT-21 | 237 | 93 | |
NRGHN010 | HER2+ SGC, T-DM1 vs TH | 30-SEP-22 | 141 | 42 | |
R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 349 | 111 | |
PREV | S1823 | GCT, Obs. Cohort, miRNA371 | 01-JUN-20 | 121 | 54 |
S1904 | Breast, Decision making for chemoprevention | 01-SEP-20 | 19 | 47 | |
A212102 | Blind Ref Set for Multicancer Early Detection | 01-AUG-22 | 193 | 83 | |
EA1151 | Prev, Tomosynthesis Mammographic Screening | 06-JUL-17 | 239 | 92 | |
EA2185 | Panc, Impact of Panc Cyst Surveillance | 16-JAN-20 | 118 | 70 | |
EA8184 | Pros, Dbl Blind GTC vs Placebo | 20-MAY-21 | 72 | 38 | |
NRGCC008 | Ovar, BRCA1, non-inferiority of BLS vs BSO | 23-JUN-20 | 281 | 130 | |
SURV | S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 227 | 92 |
SXQOL | S1600 | Bladder,Radical Cystectomy Outcomes Nutrition | 21-FEB-19 | 150 | 39 |
S2010 | ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 17-JAN-23 | 216 | 94 | |
S2013 | I-CHECKIT: ICI toxicity risk prediction study | 16-AUG-21 | 200 | 103 | |
S2205 | ICE COMPRESS: Reduction of CIPN from Taxanes | 16-MAR-23 | 11 | 26 | |
A221805 | Colorectal, Duloxetine for Oxaliplatin CIPN | 01-MAY-20 | 245 | 110 | |
A222004 | Mult, Olanza vs Megestrol for Anorexia | 15-OCT-21 | 0 | 49 | |
EAQ202 | Improving AYA PROs in EA Trials | 28-OCT-21 | 62 | 28 | |
NRGCC010 | Endo, Stg I, LN Map for LE Limb Dysfunction | 19-SEP-22 | 74 | 25 |